In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 1.24 million shares changing hands with its beta currently measuring 0.37. Company’s recent per share price level of $2.56 trading at $0.12 or 4.92% at ring of the bell on the day assigns it a market valuation of $754.36M. That closing price of ABCL’s stock is at a discount of -136.33% from its 52-week high price of $6.05 and is indicating a premium of 8.59% from its 52-week low price of $2.34. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.96 million shares which gives us an average trading volume of 1.83 million if we extend that period to 3-months.
For AbCellera Biologics Inc (ABCL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.17 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Upright in the green during last session for gaining 4.92%, in the last five days ABCL remained trading in the red while hitting it’s week-highest on Friday, 09/20/24 when the stock touched $2.56 price level, adding 6.23% to its value on the day. AbCellera Biologics Inc’s shares saw a change of -55.17% in year-to-date performance and have moved -6.57% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of -1.92% in past 30-days. Number of shares sold short was 16.84 million shares which calculate 7.86 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29 to the stock, which implies a rise of 91.17% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 34. It follows that stock’s current price would drop -95.31% in reaching the projected high whereas dropping to the targeted low would mean a loss of -95.31% for stock’s current value.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Statistics highlight that AbCellera Biologics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -42.98% of value to its shares in past 6 months, showing an annual growth rate of -7.84% while that of industry is 17.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -11.60% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.95M for the same. And 8 analysts are in estimates of company making revenue of 8.24M in the next quarter. Company posted 11.84M and 9.18M of sales in current and next quarters respectively a year earlier.
In 2024, company’s earnings growth rate is likely to be around 6.97% while estimates for its earnings growth in next 5 years are of 10.00%.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Insiders are in possession of 28.05% of company’s total shares while institution are holding 41.52 percent of that, with stock having share float percentage of 57.71%. Investors also watch the number of corporate investors in a company very closely, which is 41.52% institutions for AbCellera Biologics Inc that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at ABCL for having 27.53 million shares of worth $81.48 million. And as of 2024-06-30, it was holding 9.4033 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 21.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4852 of outstanding shares, having a total worth of $64.86 million.
